Home Featured

Featured

Random

Industry and Researchers Respond to ICER Report on MDMA-Assisted Therapy, Which Maintains Lykos’ Clinical Evidence Is “Insufficient”

The Top 5 Psychedelic Clinical Trials of 2022

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

The World Boxing Council and Wesana Health Announce Multi-Year Joint Efforts...

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum...

Early Clinical Research History of DMT

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes...

MindMed Announces $50 Million Bought Deal Public Offering

Numinus to Begin Trading on the OTC Under Symbol NUMIF

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully...

COMPASS Pathways plc announces second quarter 2022 financial results and business...

Opening the Mushroom Pharmacopeia: The Case of Norbaeocystin

12 3...316 Page 1 of 316

EDITOR PICKS

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an...

Music in Psychedelic-Assisted Therapy: An Introduction to Sound, Playlist Curation, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.